Market revenue in 2023 | USD 27.9 million |
Market revenue in 2030 | USD 73.2 million |
Growth rate | 14.8% (CAGR from 2023 to 2030) |
Largest segment | Pure prp |
Fastest growing segment | Leukocyte Rich PRP |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pure PRP, Leukocyte Rich PRP |
Key market players worldwide | Johnson & Johnson, Arthrex, Terumo Corp, Zimmer Biomet Holdings Inc, Stryker Corp, EmCyte Corporation, Dr. PRP USA, Juventix Regenerative Medical, APEX Biologix, Celling Biosciences |
Pure prp was the largest segment with a revenue share of 50.9% in 2023. Horizon Databook has segmented the China platelet rich plasma (prp) market based on pure prp, leukocyte rich prp covering the revenue growth of each sub-segment from 2018 to 2030.
China is one of the key contributors to Asia Pacific’s revenue generation, with the fastest growth rate over the forecast period. The application of PRP therapy is increasing in the field of dermatology. Several clinical studies have reported the clinical efficacy of PRP therapy in this field.
For instance, a study was published in August 2020 by a group of scientists in China to assess the progress in using PRP in medical & esthetic dermatology. This study was a collaborative, non-funded study between hospitals and universities in China.
In January 2018, a group of doctors published research that includes the evaluation of benefits offered by intraosseous infiltration combined with intra-articular injection of PRP for the treatment of mild and moderate stages of knee joint degeneration.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account